Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability.

Psychiatry research - 1 Jun 2022

Joković Danilo, Milosavljević Filip, Stojanović Zvezdana, Šupić Gordana, Vojvodić Danilo, Uzelac Bojana, Jukić Marin M, Petković Ćurčin Aleksandra

Abstract excerpt

The inter-individual variability in CYP2C19-mediated metabolism may affect the antidepressant treatment. The aim of this study is to evaluate differences in antidepressant efficacy and tolerability between different CYP2C19 metabolizer categories in inpatients suffering from major depressive disorder. The cohort was divided into experimental groups based on CYP2C19 genotype and it contained 24 slow (SMs), 41...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to Drug-Related Side Effects and Adverse Reactions

Share to Genotype

Share to Phenotype

Source

Identifiers

PMID: 35398660
DOI: 10.1016/j.psychres.2022.114535

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability.PMID 35398660Read ↗

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studiesSemantic proximity Read ↗

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.Semantic proximity Read ↗

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression StudySemantic proximity Read ↗

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK BiobankSemantic proximity Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIsSemantic proximity Read ↗

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.Semantic proximity Read ↗

The impact of CYP allelic variation on antidepressant metabolism: a review.Semantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort studySemantic proximity Read ↗

Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.